Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index falling 2.6% and the Health Care Select Sector SPDR Fund (XLV) dropping 2.3%.
The iShares Biotechnology ETF (IBB) shed 1.5%.
In corporate news, UnitedHealth (UNH) suspended its full-year outlook amid higher-than-expected medical costs, while Andrew Witty stepped down as chief executive due to "personal reasons." UnitedHealth shares fell more than 16%.
Alumis (ALMS) shares fell past 8%. Shareholders of Alumis and
Acelyrin (SLRN) separately approved their merger deal at special meetings. Acelyrin shares also fell over 9%.
CNS Pharmaceuticals (CNSP) shares jumped 35% after the company said it has acquired from Cortice Biosciences an orphan drug designation for late-stage abeotaxane TPI 287 as a potential treatment for glioblastoma multiforme.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。